Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 5/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.40 |
| ▸ | KHK | P50053 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4923903 | 0.89 | RPS6KB1 (0.39) | MAP3K12RPS6KB1AKT1 | |
| SCHEMBL4920729 | 0.88 | HSD17B10 (0.47) | MAPK1HSD17B10MAP3K12FAAHL3MBTL1 | |
| SCHEMBL4928254 | 0.87 | SYK (0.45) | SYKMAPK1HSD17B10MAP3K12KHK | |
| SCHEMBL4931945 | 0.84 | PIK3CA (0.46) | MAPK1HSD17B10MAP3K12L3MBTL1RPS6KB1 | |
| SCHEMBL14184758 | 0.83 | SCN9A (0.42) | MAPK1HSD17B10FAAHRPS6KB1AKT1 | |
| SCHEMBL4928603 | 0.82 | HSD17B10 (0.41) | SYKMAPK1HSD17B10MAP3K12FAAH | |
| SCHEMBL4929606 | 0.81 | HTR2B (0.46) | SYKMAPK1HSD17B10MAP3K12KHK | |
| SCHEMBL4930043 | 0.79 | KHK (0.46) | SYKMAPK1HSD17B10MAP3K12KHK | |
| SCHEMBL4930822 | 0.79 | HSD17B10 (0.44) | SYKMAPK1HSD17B10MAP3K12KHK | |
| SCHEMBL14184766 | 0.78 | MTOR (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| EP-1838703-A2 | HETEROARYL SUBSTITUTED PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006078992-A2 | HETEROARYL SUBSTITUTED PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | SYK 2136/4885MAPK1 3040/4885HSD17B10 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.